Trial Profile
A Retrospective Cohort Study to Assess Predicted Rate and Associated Factors of Dabigatran-induced Bleeding Events in Patients with Non-Valvular Atrial Fibrillation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2018
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Embolism and thrombosis
- Focus Adverse reactions
- 31 Jul 2018 New trial record